



Public notification regarding availability of Meda's 2008 new share issue prospectus

The board of Meda AB (publ) has prepared a prospectus regarding the new share issue with preferential rights for Meda's shareholders. The prospectus is displayed at and available from www.meda.se and www.danskebank.se.

The prospectus is also available free of charge from Meda AB, Box 906, SE-170 09 Solna, Sweden; phone: +46 8 630 19 00 or from Danske Markets, Norrmalmstorg 1, SE-103 92 Stockholm, Sweden.

Direct registered Meda shareholders as of 5 November 2008 will receive the prospectus via regular mail.

Meda Aktiebolag (publ)

For more information contact:

Anders Larnholt, VP Investor Relations

Phone. +46 709 458 878

This press release may not be announced, published or disseminated, directly or indirectly, in the United States of America, Canada, Australia, Hong Kong, Japan or in any other country where such measure wholly or partly is subject to restrictions by law. The information in this press release may not be forwarded, reproduced or shown in way that is in conflict with such restrictions. Failure to comply with this instruction may constitute a crime according the United States Securities Act of 1933 ("Securities Act") or applicable laws in other jurisdictions.

Nothing in this press release shall be deemed to constitute and offer to invest, subscribe or otherwise deal with shares, subscription right or other securities of Meda.

Neither the subscription right, nor the paid and subscribed shares or the new shares will be registered according the Securities Act or any provincial law in Canada and may not be transferred or offered for sale in the USA or Canada, or to a person domiciled in such state or for such persons account other in excepted cases, where registration is not required according the Securities act or any provincial law in Canada.

This information is such which Meda is obliged to make public according the Financial Markets Act and the Financial Instruments Trading Act (Sw: lagen om värdepappersmarknaden and lagen om handel med finansiella instrument). The information has been submitted for publication on November 5, 2008.

MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.